2107. Correlation of Specific Mutations in Line Probe Assay (LPA) and Drug Susceptibility Test (DST) with respect to Fluoroquinolone Resistance in Drug Resistant Mycobacterium tuberculosis
Session: Poster Abstract Session: Diagnostics Mycobacteriology
Saturday, October 7, 2017
Room: Poster Hall CD
Posters
  • IDSA mod final.pdf (782.8 kB)
  • Background:

    This study was done to investigate the utility of specific fluoroquinolone mutations in LPA in predicting the susceptibility in DST at WHO recommended Critical Concentrations of 0.5µg/dL and 2µg/dL of moxifloxacin within a short time frame as provided by LPA.

    Methods:

    In a retrospective study performed at a tertiary care hospital of Mumbai, India from October 2015 to February 2017, consecutive samples demonstrating fluoroquinolone resistance by LPA were selected. The LPA kit used was Hain Lifescience Genotype MTBDRsl (Version 1). It detects the following mutations in gyrA gene: MUT1: Ala90Val, MUT2: Ser91Pro, MUT3A: Asp94Ala, MUT3B: Asp94Asn/Tyr, MUT3C: Asp94Gly, MUT3D: Asp94His. The causal mutation was noted. For 89 of these samples, DST had been requested & results with Critical Concentration of 0.5µg/dL and 2µg/dL for moxifloxacin were available

    Results:

    The 89 samples studied were as follows: Sputum (n=60), paravertebral soft tissue (n=2), bronchoalveolar fluid (n=2), cerebrospinal fluid (n=1), endotracheal tube secretion (n=1), pleural fluid (n=1) and site not recorded (22). 3 of these samples had double mutations. Results are as follows.

    Mutation in gyrA gene

    Number of  samples (n)

    Susceptible at 0.5µg/dL [n(%)]

    Susceptible at 2µg/dL [n(%)]

    MUT1 (Ala90Val)

    18

    6(33.33)

    16(88.89)

    MUT2 (Ser91Pro)

    2

    0(0)

    1(50)

    MUT3A (Asp94Asn)

    13

    3(23.07)

    11(84.61)

    MUT3B (Asp94Asn/Tyr)

    6

    1(16.67)

    4(66.67)

    MUT3C (Asp94Gly)

    51

    4(8)

    43(84.31)

    MUT3D (Asp94His)

    2

    0(0)

    2(100)

    Conclusion:

    This study showed a higher proportion of M. tuberculosis susceptibility at 2µg/dL rather than at 0.5µg/dL, to moxifloxacin for gyrA mutations Ala90Val (MUT1), Asp94Ala (MUT3A), Asp94Gly (MUT3C), Asp94His (MUT3D) but not for Ser91Pro (MUT2) & Asp94Asn/Tyr (MUT3B). However, the number of samples with Ser91Pro (MUT2) & Asp94Asn/Tyr (MUT3B) mutations was too small for meaningful conclusion.

    This susceptibility at a higher critical concentration of moxifloxacin may have clinical implications for use of high dose moxifloxacin. Since this information is available within a short time frame as provided by LPA, a more effective regimen could be devised 4 to 8 weeks earlier than after results of DST. This may result in faster sputum conversion & prevent amplification of resistance.

     

     

     

     

    Umang Agrawal, DNB, MRCP, Pratik Savaj, DNB, Kanishka Davda, DNB, Camilla Rodrigues, MD and Rajeev Soman, MD, FIDSA, PD Hinduja National Hospital and Medical Research Centre, Mumbai, India

    Disclosures:

    U. Agrawal, None

    P. Savaj, None

    K. Davda, None

    C. Rodrigues, None

    R. Soman, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.